Risankizumab Shows Efficacy, Tolerability in Patients With PsA Risankizumab Shows Efficacy, Tolerability in Patients With PsA

More than half of participants receiving risankizumab achieved the primary endpoint of at least 20% improvement in ACR response criteria.Medscape Medical News
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Rheumatology News Source Type: news